Children receiving intermediate, high dose MTX experience poor CINV control
the ONA take:
Children with cancer receiving methotrexate had a poor complete chemotherapy-induced nausea and vomiting (CINV) rate, both in the acute and delayed phases, according to a new study published in the journal Supportive Care in Cancer.
For the prospective study, 30 children received intermediate-dose (ID-MTX: >1 to <12/g/m2/dose) or high-dose methotrexate (HD-MTX: ≥12 g/m2/dose). CINV prophylaxis was provided to pediatric patients at the discretion of the clinician.
Researchers documented antiemetic administration, nausea severity, and emetic episodes during the acute phase (for 24 hours from the start of the methotrexate infusion) and the delayed phase (for up to a further 168 hours).
Researchers found that CINV prophylaxis received ondansetron or granisetron plus dexamethasone or nabilone. Results showed that among the 10 patients that received HD-MTX, 0% achieved complete control during the acute phase and 30% experienced complete control in the delayed phase.
Among the 20 patients that received ID-MTX, the complete control rates were 20% and 5% in the acute and delayed phase, respectively.
The findings confirm the classification of HD-MTX as highly emetogenic chemotherapy and suggest that ID-be reclassified as highly emetogenic chemotherapy, as well.
Children with cancer receiving methotrexate had a poor complete chemotherapy-induced nausea and vomiting (CINV) rate.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|